Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Daan G. Knapen, MD +31 50 3616161
d.g.knapen@umcg.nl


Elisabeth GE de Vries, MD, PhD +31 50 3612934
e.g.e.de.vries@umcg.nl


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - CD8 PET Imaging in Metastatic Solid Tumours
Back

CD8 PET Imaging in Metastatic Solid Tumours

Recruiting

Open to: ALL

Age: 18.0 - N/A

Cambridge

Medical Conditions

Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2025 Nov 2028

INTERVENTIONAL

Intervention Type : RADIATION
Intervention Description : 89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.

After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab.

Intervention Arm Group : CD8 PET imaging;

Intervention Type : DRUG
Intervention Description : Immunotherapy treatment with Nivolumab

Intervention Arm Group : CD8 PET imaging;

Intervention Type : DRUG
Intervention Description : Immunotherapy treatment with cetrelimab

Intervention Arm Group : CD8 PET imaging;

Intervention Type : OTHER
Intervention Description : 89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later

Intervention Arm Group : CD8 PET imaging;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University of Cambridge
    Cambridge
    CB2 1TN

Elisabeth GE de Vries, MD, PhD +31 50 3612934
e.g.e.de.vries@umcg.nl


Daan G. Knapen, MD +31 50 3616161
d.g.knapen@umcg.nl



The study is sponsored by University Medical Center Groningen



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06534190
Last updated 28 March 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top